Cargando…

Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process

AIM: To clarify the immune cellular changes in critically ill patients recovering from coronavirus disease 2019 (COVID‐19). METHODS: The immune response of peripheral blood mononuclear cells from patients with severe COVID‐19 in different stages of recovery (3, 6, and 12 months from hospitalization)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsuyama, Yumi, Yamakawa, Kazuma, Kayano, Katsuhide, Maruyama, Miho, Umemura, Yutaka, Wada, Takeshi, Fujimi, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597380/
https://www.ncbi.nlm.nih.gov/pubmed/36311179
http://dx.doi.org/10.1002/ams2.803
_version_ 1784816079240953856
author Mitsuyama, Yumi
Yamakawa, Kazuma
Kayano, Katsuhide
Maruyama, Miho
Umemura, Yutaka
Wada, Takeshi
Fujimi, Satoshi
author_facet Mitsuyama, Yumi
Yamakawa, Kazuma
Kayano, Katsuhide
Maruyama, Miho
Umemura, Yutaka
Wada, Takeshi
Fujimi, Satoshi
author_sort Mitsuyama, Yumi
collection PubMed
description AIM: To clarify the immune cellular changes in critically ill patients recovering from coronavirus disease 2019 (COVID‐19). METHODS: The immune response of peripheral blood mononuclear cells from patients with severe COVID‐19 in different stages of recovery (3, 6, and 12 months from hospitalization) was evaluated by single‐cell mass cytometry. Immunological changes in patients were compared with those in age‐matched healthy donors. RESULTS: Three patients with severe COVID‐19 were compared with four healthy donors. In the patients, there was an increase in the cell density of CD4‐ and CD8‐positive T lymphocytes, and B cells, over the course of the recovery period. CD4‐ and CD8‐positive T lymphocytes expressing T‐bet and granzyme B (Gzm B) in patients were abundant during all recovery periods. The level of regulatory T cells remained high throughout the year. The levels of natural killer (NK) cells in patients were higher than in those in the healthy donors, and the frequency of CD16(+) NK cells expressing Gzm B increased throughout the year. CONCLUSION: Patients recovering from severe COVID‐19 showed persistence of cytotoxic lymphocytes, NK cells, and regulatory T cells throughout the posthospitalization year of recovery.
format Online
Article
Text
id pubmed-9597380
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95973802022-10-27 Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process Mitsuyama, Yumi Yamakawa, Kazuma Kayano, Katsuhide Maruyama, Miho Umemura, Yutaka Wada, Takeshi Fujimi, Satoshi Acute Med Surg Original Articles AIM: To clarify the immune cellular changes in critically ill patients recovering from coronavirus disease 2019 (COVID‐19). METHODS: The immune response of peripheral blood mononuclear cells from patients with severe COVID‐19 in different stages of recovery (3, 6, and 12 months from hospitalization) was evaluated by single‐cell mass cytometry. Immunological changes in patients were compared with those in age‐matched healthy donors. RESULTS: Three patients with severe COVID‐19 were compared with four healthy donors. In the patients, there was an increase in the cell density of CD4‐ and CD8‐positive T lymphocytes, and B cells, over the course of the recovery period. CD4‐ and CD8‐positive T lymphocytes expressing T‐bet and granzyme B (Gzm B) in patients were abundant during all recovery periods. The level of regulatory T cells remained high throughout the year. The levels of natural killer (NK) cells in patients were higher than in those in the healthy donors, and the frequency of CD16(+) NK cells expressing Gzm B increased throughout the year. CONCLUSION: Patients recovering from severe COVID‐19 showed persistence of cytotoxic lymphocytes, NK cells, and regulatory T cells throughout the posthospitalization year of recovery. John Wiley and Sons Inc. 2022-10-26 /pmc/articles/PMC9597380/ /pubmed/36311179 http://dx.doi.org/10.1002/ams2.803 Text en © 2022 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Mitsuyama, Yumi
Yamakawa, Kazuma
Kayano, Katsuhide
Maruyama, Miho
Umemura, Yutaka
Wada, Takeshi
Fujimi, Satoshi
Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process
title Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process
title_full Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process
title_fullStr Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process
title_full_unstemmed Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process
title_short Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process
title_sort residual persistence of cytotoxicity lymphocytes and regulatory t cells in patients with severe coronavirus disease 2019 over a 1‐year recovery process
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597380/
https://www.ncbi.nlm.nih.gov/pubmed/36311179
http://dx.doi.org/10.1002/ams2.803
work_keys_str_mv AT mitsuyamayumi residualpersistenceofcytotoxicitylymphocytesandregulatorytcellsinpatientswithseverecoronavirusdisease2019overa1yearrecoveryprocess
AT yamakawakazuma residualpersistenceofcytotoxicitylymphocytesandregulatorytcellsinpatientswithseverecoronavirusdisease2019overa1yearrecoveryprocess
AT kayanokatsuhide residualpersistenceofcytotoxicitylymphocytesandregulatorytcellsinpatientswithseverecoronavirusdisease2019overa1yearrecoveryprocess
AT maruyamamiho residualpersistenceofcytotoxicitylymphocytesandregulatorytcellsinpatientswithseverecoronavirusdisease2019overa1yearrecoveryprocess
AT umemurayutaka residualpersistenceofcytotoxicitylymphocytesandregulatorytcellsinpatientswithseverecoronavirusdisease2019overa1yearrecoveryprocess
AT wadatakeshi residualpersistenceofcytotoxicitylymphocytesandregulatorytcellsinpatientswithseverecoronavirusdisease2019overa1yearrecoveryprocess
AT fujimisatoshi residualpersistenceofcytotoxicitylymphocytesandregulatorytcellsinpatientswithseverecoronavirusdisease2019overa1yearrecoveryprocess